Analyzing Titan Pharmaceuticals (NASDAQ:TTNP) & ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics (NASDAQ:ADMA) and Titan Pharmaceuticals (NASDAQ:TTNP) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Valuation & Earnings

This table compares ADMA Biologics and Titan Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$330.24 million	13.88	-$28.24 million	($0.02)	-988.50
Titan Pharmaceuticals	$180,000.00	26.31	-$5.57 million	N/A	N/A

Titan Pharmaceuticals has lower revenue, but higher earnings than ADMA Biologics.

Volatility and Risk

ADMA Biologics has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500.

Insider and Institutional Ownership

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by company insiders. Comparatively, 24.9% of Titan Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for ADMA Biologics and Titan Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0	0	3	1	3.25
Titan Pharmaceuticals	0	0	0	0	N/A

ADMA Biologics presently has a consensus target price of $15.50, suggesting a potential downside of 21.60%. Given ADMA Biologics’ higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Titan Pharmaceuticals.

Profitability

This table compares ADMA Biologics and Titan Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	10.53%	38.79%	17.35%
Titan Pharmaceuticals	N/A	-87.90%	-75.11%

Summary

ADMA Biologics beats Titan Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.